<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39468662</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-6512</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Stem cell research &amp; therapy</Title><ISOAbbreviation>Stem Cell Res Ther</ISOAbbreviation></Journal><ArticleTitle>Evaluating the therapeutic potential of different sources of mesenchymal stem cells in acute respiratory distress syndrome.</ArticleTitle><Pagination><StartPage>385</StartPage><MedlinePgn>385</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13287-024-03977-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mesenchymal stem/stromal cells (MSCs) have attracted interest as a potential therapy given their anti-inflammatory and immunomodulatory properties. However, clinical trials using MSCs for acute respiratory distress syndrome (ARDS) have produced mixed and inconclusive data. In previous work, we performed a "head-to-head" comparison between different sources of MSCs and showed that each source had a unique genomic and proteomic "signature".</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This study investigated which sources of MSC: bone marrow derived-MSCs (BM-MSCs), adipose tissue derived-MSCs (AD-MSCs) and umbilical cord derived-MSCs (UC-MSCs)  would be the optimal candidate to be used as a therapy in an LPS-induced mouse model of ARDS. Immune cells assessment, tissue transcriptomics, animal survival, and endothelial-epithelial barrier assessment were used to evaluate their effects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When comparing the three most commonly used MSC sources, we found that UC-MSCs exhibited greater efficacy compared to other MSCs in improving animal survival, mitigating epithelial/endothelial damage, decreasing lung inflammation via reducing neutrophil infiltration, T cell proliferation, and M1 polarization. Bulk RNA sequencing of lung tissue also showed that UC-MSCs have the capability to downregulate extracellular trap formation, by the downregulation of key genes like Elane and Padi4. Notably, treatment with UC-MSCs demonstrated a significant reduction in Fc-γ R mediated phagocytosis, which has been associated with monocyte pyroptosis and intense inflammation in the context of COVID-19.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings suggest that UC-MSCs are an optimal source of MSC to treat acute inflammatory conditions in the lungs, such as ARDS.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Regmi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Interventional Radiology Innovation at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganguly</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Interventional Radiology Innovation at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Blood and Marrow Transplantation and Cellular Therapy, School of Medicine, Stanford University, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Primavera</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Interventional Radiology Innovation at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chetty</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Interventional Radiology Innovation at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interventional Radiology Innovation at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Shaini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Interventional Radiology Innovation at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakor</LastName><ForeName>A S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0001-7395-0515</Identifier><AffiliationInfo><Affiliation>Interventional Radiology Innovation at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94304, USA. asthakor@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stem Cell Res Ther</MedlineTA><NlmUniqueID>101527581</NlmUniqueID><ISSNLinking>1757-6512</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014470" MajorTopicYN="N">Umbilical Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">Immune responses</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">Umbilical cord</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>1</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39468662</ArticleId><ArticleId IdType="doi">10.1186/s13287-024-03977-w</ArticleId><ArticleId IdType="pii">10.1186/s13287-024-03977-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banavasi H, Nguyen P, Osman H, Soubani AO. Management of ARDS - what works and what does not. Am J Med Sci. 2021;362(1):13–23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2020.12.019</ArticleId><ArticleId IdType="pubmed">34090669</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah TG, Predescu D, Predescu S. Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options. Clin Transl Med. 2019;8(1):1–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-019-0242-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao K, Hou F, Huang X, Li B, Qian ZR, Xie L. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell Res Ther. 2020;11(1):305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-01804-6</ArticleId><ArticleId IdType="pubmed">32698898</ArticleId><ArticleId IdType="pmc">7373844</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Chen QH, Liu AR, Xu XP, Han JB, Qiu HB. Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway. Stem Cell Res Ther. 2015;6:250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-015-0257-0</ArticleId><ArticleId IdType="pubmed">26674641</ArticleId><ArticleId IdType="pmc">4682264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW, Gupta N, Serikov V, Matthay MA. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther. 2009;9(10):1259–70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712590903213651</ArticleId><ArticleId IdType="pubmed">19691441</ArticleId><ArticleId IdType="pmc">2852252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y-X, Xu J-F, Seeley EJ, Tang X-D, Xu L-L, Zhu Y-G, et al. Adipose tissue-derived mesenchymal stem cells attenuate pulmonary infection caused by pseudomonas aeruginosa via inhibiting overproduction of prostaglandin E2. Stem Cells. 2015;33(7):2331–42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1996</ArticleId><ArticleId IdType="pubmed">25788456</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson MV, Morrison TJ, Doherty DF, McAuley DF, Matthay MA, Kissenpfennig A, et al. Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells. 2016;34(8):2210–23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2372</ArticleId><ArticleId IdType="pubmed">27059413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarov I, Lee JW, Soupene E, Etemad S, Knapik D, Green W, et al. Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential. Stem Cells Transl Med. 2012;1(5):359–72.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2011-0021</ArticleId><ArticleId IdType="pubmed">23197815</ArticleId><ArticleId IdType="pmc">3635148</ArticleId></ArticleIdList></Reference><Reference><Citation>Curley GF, Jerkic M, Dixon S, Hogan G, Masterson C, O’Toole D, et al. Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent Escherichia coli–induced acute respiratory distress syndrome. Crit Care Med. 2017;45(2):e202–12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002073</ArticleId><ArticleId IdType="pubmed">27861182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguly A, Swaminathan G, Garcia-Marques F, Regmi S, Yarani R, Primavera R, et al. Integrated transcriptome-proteome analyses of human stem cells reveal source-dependent differences in their regenerative signature. Stem Cell Reports. 2023;18(1):190–204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2022.11.006</ArticleId><ArticleId IdType="pubmed">36493779</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke L, Job ER, Saelens X, Roose K. Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration. J Vis Exp. 2017. https://doi.org/10.3791/55398 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/55398</ArticleId><ArticleId IdType="pubmed">28518083</ArticleId><ArticleId IdType="pmc">5607888</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics (Oxford, England). 2015;31(2):166–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Regmi S, Pathak S, Thanh TP, Nguyen TT, Sung J-H, Yook S, et al. Intraportally delivered stem cell spheroids localize in the liver and protect hepatocytes against GalN/LPS-induced fulminant hepatic toxicity. Stem Cell Res Ther. 2019;10(1):230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-019-1337-3</ArticleId><ArticleId IdType="pubmed">31615539</ArticleId><ArticleId IdType="pmc">6794806</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. Gene Ontol Consort Nat genet. 2000;25(1):25–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology resource: enriching a GOld mine. Nucleic acids research. 2021;49(D1):D325-d34.</Citation></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216–21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac194</ArticleId><ArticleId IdType="pubmed">35325185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda M, Xin Y, Goffi A, Herrmann J, Kaczka DW, Kavanagh BP, et al. Imaging the injured lung: mechanisms of action and clinical use. Anesthesiology. 2019;131(3):716–49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000002583</ArticleId><ArticleId IdType="pubmed">30664057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya J, Matthay MA. Regulation and repair of the alveolar-capillary barrier in acute lung injury. Annu Rev Physiol. 2013;75:593–615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-030212-183756</ArticleId><ArticleId IdType="pubmed">23398155</ArticleId></ArticleIdList></Reference><Reference><Citation>Keir HR, Chalmers JD. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. Eur Respir Rev. 2022;31(163):210241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0241-2021</ArticleId><ArticleId IdType="pubmed">35197267</ArticleId><ArticleId IdType="pmc">9488971</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Li H, Mao Z, Peng L, Liu B, Lin F, et al. Delayed neutrophil apoptosis may enhance NET formation in ARDS. Respir Res. 2022;23(1):155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02065-y</ArticleId><ArticleId IdType="pubmed">35698192</ArticleId><ArticleId IdType="pmc">9190136</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Okada H, Takemura G, Takada C, Kuroda A, Yano H, et al. Neutrophil elastase damages the pulmonary endothelial glycocalyx in lipopolysaccharide-induced experimental endotoxemia. Am J Pathol. 2019;189(8):1526–35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2019.05.002</ArticleId><ArticleId IdType="pubmed">31108101</ArticleId></ArticleIdList></Reference><Reference><Citation>Aratani Y. Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018;640:47–52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2018.01.004</ArticleId><ArticleId IdType="pubmed">29336940</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136(10):1169–79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007008</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesta MC, Zippoli M, Marsiglia C, Gavioli EM, Cremonesi G, Khan A, et al. Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis. Eur J Immunol. 2023;53(1):2250010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202250010</ArticleId><ArticleId IdType="pubmed">36239164</ArticleId></ArticleIdList></Reference><Reference><Citation>Son S, Yoon S-H, Chae BJ, Hwang I, Shim D-W, Choe YH, et al. Neutrophils facilitate prolonged inflammasome response in the damp-rich inflammatory milieu. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.746032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746032</ArticleId><ArticleId IdType="pubmed">34659244</ArticleId><ArticleId IdType="pmc">8511454</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Li H, Li Y, Dai M, Zhang L, Liu S, et al. NETs promote ALI/ARDS inflammation by regulating alveolar macrophage polarization. Exp Cell Res. 2019;382(2): 111486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2019.06.031</ArticleId><ArticleId IdType="pubmed">31255598</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Zhang Y, Wang Y. Immunotherapy strategies and prospects for acute lung injury: Focus on immune cells and cytokines. Front Pharmacol. 2022;13:1103309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1103309</ArticleId><ArticleId IdType="pubmed">36618910</ArticleId><ArticleId IdType="pmc">9815466</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosyreva A, Dzhalilova D, Lokhonina A, Vishnyakova P, Fatkhudinov T. The role of macrophages in the pathogenesis of SARS-CoV-2-associated acute respiratory distress syndrome. Front Immunol. 2021;12: 682871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.682871</ArticleId><ArticleId IdType="pubmed">34040616</ArticleId><ArticleId IdType="pmc">8141811</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Hernandez M, Sotomayor EM, Villagra A. Targeting macrophages as a therapeutic option in coronavirus disease 2019. Front Pharmacol. 2020;11: 577571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.577571</ArticleId><ArticleId IdType="pubmed">33324210</ArticleId><ArticleId IdType="pmc">7723423</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo Â, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J, et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606(7914):576–84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId><ArticleId IdType="pmc">10071495</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Peng D, You J, Zhou O, Qiu H, Hao C, et al. Type 2 alveolar epithelial cells differentiated from human umbilical cord mesenchymal stem cells alleviate mouse pulmonary fibrosis through β-catenin-regulated cell apoptosis. Stem Cells Dev. 2021;30(13):660–70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2020.0208</ArticleId><ArticleId IdType="pubmed">33899513</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XY, Chen KY, Feng PH, Lee KY, Fang YT, Chen YY, et al. YAP-regulated type II alveolar epithelial cell differentiation mediated by human umbilical cord-derived mesenchymal stem cells in acute respiratory distress syndrome. Biomed Pharmacother. 2023;159: 114302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.114302</ArticleId><ArticleId IdType="pubmed">36701989</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(18)30418-1</ArticleId><ArticleId IdType="pubmed">30455077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowdish ME, Barkauskas CE, Overbey JR, Gottlieb RL, Osman K, Duggal A, et al. A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19. Am J Respir Crit Care Med. 2023;207(3):261–70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202201-0157OC</ArticleId><ArticleId IdType="pubmed">36099435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660–73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.20-0472</ArticleId><ArticleId IdType="pubmed">33400390</ArticleId><ArticleId IdType="pmc">8046040</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh M, Vaezi AA, Aliannejad R, Sohrabpour AA, Kiaei SZF, Shadnoush M, et al. Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res Ther. 2021;12(1):410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-021-02483-7</ArticleId><ArticleId IdType="pubmed">34271988</ArticleId><ArticleId IdType="pmc">8283394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian SR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12(1):91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-021-02165-4</ArticleId><ArticleId IdType="pubmed">33514427</ArticleId><ArticleId IdType="pmc">7844804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. Stem Cells Transl Med. 2021;10(9):1279–87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.21-0046</ArticleId><ArticleId IdType="pubmed">34102020</ArticleId><ArticleId IdType="pmc">8242692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, et al. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Res Ther. 2022;13(1):283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-02920-1</ArticleId><ArticleId IdType="pubmed">35765103</ArticleId><ArticleId IdType="pmc">9241239</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Zheng Y, Cheng Z, Ji N, Niu C, Wang Y, et al. One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment. Stem Cell Res Ther. 2022;13(1):321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-02972-3</ArticleId><ArticleId IdType="pubmed">35842684</ArticleId><ArticleId IdType="pmc">9288258</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care. 2022;26(1):48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03930-4</ArticleId><ArticleId IdType="pubmed">35189925</ArticleId><ArticleId IdType="pmc">8860258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>